MEDICAMEQ

- Medicamen Biotech Limited informed about the Record Date and Book Closure for its 33rd Annual General Meeting (AGM) and payment of the Final Dividend for the Financial Year 2025-26. - Record Date: Saturday, September 19, 2026. - Book Closure: Sunday, September 20, 2026, to Saturday, September 26, 2026 (both days inclusive). - The Final Dividend has been recommended by the Board of Directors, subject to approval at the AGM.

- Q1 FY27 Consolidated Revenue ₹4,875.85 Lakh vs ₹4,351.50 Lakh (▲12.05% YoY) - EBITDA ₹432.58 Lakh vs ₹461.53 Lakh (▼6.27% YoY) - PAT ₹184.60 Lakh vs ₹160.05 Lakh (▲15.34% YoY) - EBITDA Margin 8.87% vs 10.61% (▼174 bps) - Board approved a final dividend of Re. 1/- per equity share (10%). - Noted non-compliance with SEBI LODR Regulations, including for Nomination and Remuneration Committee composition; fines aggregating to ₹1,10,920 were paid.

- Q1 FY27 Consolidated Operating Revenue ₹4,789.69 Lakhs vs ₹4,304.48 Lakhs (▲11.27% YoY) - EBITDA ₹518.74 Lakhs vs ₹508.56 Lakhs (▲2.0% YoY) - PAT ₹184.60 Lakhs vs ₹160.05 Lakhs (▲15.34% YoY) - EBITDA Margin 10.64% vs 11.69% (▼105bps) - Board approved a Final Dividend of Re. 1/- per equity share (10%) for FY26, subject to shareholder approval at the upcoming 33rd Annual General Meeting (AGM). - The 33rd AGM will be held on September 26, 2026. - The company received fines of ₹1,10,920 each from BSE and NSE for non-compliance with SEBI LODR Regulation 19(1)/19(2) regarding the composition of the Nomination and Remuneration Committee; these fines have been paid.

- Q1 FY27 Consolidated Revenue ₹4,875.85 Cr vs ₹4,351.50 Cr (▲12.05% YoY) - EBITDA ₹432.58 Cr vs ₹461.53 Cr (▼6.27% YoY) - PAT ₹184.60 Cr vs ₹160.05 Cr (▲15.34% YoY) - EBITDA Margin 9.03% vs 10.72% (▼169bps) - Board proposed a Final Dividend of 10% (₹1/- per Equity Share) for FY 2025-26. - Company noted non-compliance with SEBI LODR Regulation 19(1)/19(2) regarding the constitution of the Nomination and Remuneration Committee. - Fines of ₹1,10,920 each were levied by both BSE and NSE for this non-compliance, with potential actions like freezing promoter shares or shifting to 'Trade for Trade' if not resolved.

- Trading window to close from July 01, 2026, for designated persons. - Will reopen 48 hours after Q1 FY2027 un-audited financial results (Standalone & Consolidated) declaration for the quarter ended June 30, 2026. - Board meeting date for results approval will be intimated separately.

Consolidated Revenue for Q4 FY26 was ₹62.38 Cr vs ₹34.84 Cr (▲79.06% YoY), EBITDA ₹7.18 Cr vs ₹3.62 Cr (▲98.34% YoY), PAT ₹4.45 Cr vs ₹1.86 Cr (▲139.25% YoY). EBITDA Margin was 11.51% vs 10.39% (▲112bps). The Board also recommended a final dividend of Rs. 1.00 per equity share for FY26.

Medicamen Biotech Limited clarified an incorrect event displayed on the NSDL portal under its login. The company stated that no such event was initiated or undertaken by them, confirming it as inadvertent and non-material, and is working with NSDL for rectification.

Medicamen Biotech Limited announced the closure of its trading window for designated persons from April 01, 2026, until 48 hours post-declaration of audited financial results for the quarter and year ended March 31, 2026, to prevent insider trading.

Medicamen Biotech received a cautionary letter from NSE on Jan 27, 2026, for observations reported by the Secretarial Auditor in the Compliance Report for FY2025. The company is advised to be careful to avoid recurrence of lapses, though no impact on financials/operations is expected.

Medicamen Biotech Limited issued a corrigendum correcting the retirement date of Independent Directors Mr. Harish Pande and Mr. Arun Kumar from February 13, 2026, to February 26, 2026. They ceased to be directors effective February 26, 2026, due to completion of term.

Medicamen Biotech Limited announced that Mr. Harish Pande and Mr. Arun Kumar completed their term as Independent Directors, effective February 13, 2026. They ceased to be part of various committees. New Independent Directors were previously appointed and approved by shareholders.

Consolidated Revenue ₹4,690.85Cr vs ₹4,514.22Cr (▲4% YoY), EBITDA ₹437.54Cr vs ₹670.55Cr (▼35% YoY), PAT ₹163.47Cr vs ₹292.20Cr (▼44% YoY). EBITDA Margin 9.33% vs 14.85% (▼552bps). Additionally, two independent directors ceased their tenure.

Consolidated Revenue ₹4,744.34 Lacs vs ₹4,528.29 Lacs (▲4.8% YoY), EBITDA ₹491.03 Lacs vs ₹684.62 Lacs (▼28.3% YoY), PAT ₹163.47 Lacs vs ₹292.20 Lacs (▼44.1% YoY). EBITDA Margin 10.35% vs 15.12% (▼477bps).